NRBO Live signals | Maximize Profits with Getagraph.com

BUY 101524 min ago

@ $4.65

Issued: 14 Feb 2024 @ 15:13

Return: -33.33%

Previous signal: Feb 12 - 09:45

Previous signal: Sell

Return: -4.12 %

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases...

Stats
Today's Volume	39 259.00
Average Volume	1.35M
Market Cap	15.21M
EPS	$-2.28 ( 2024-04-04 )
Next earnings date	( $-0.780 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.260
ATR14	$0.0350 (1.13%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Woodworth Marshall H	Buy	33 496	Common Stock
2023-12-01	Tursi James Patrick	Buy	7 157	Common Stock
2023-12-01	Tursi James Patrick	Buy	25 000	Common Stock
2023-11-01	Tursi James Patrick	Buy	0
2023-10-27	Woodworth Marshall H	Buy	0

INSIDER POWER
31.79
Last 74 transactions
Buy: 14 405 360 \| Sell: 2 893 741

Neurobo Pharmaceuticals Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Neurobo Pharmaceuticals Financials

Annual	2023
Revenue:	$7 000.00
Gross Profit:	$0 (0.00 %)
EPS:	$-2.46

Q4	2023
Revenue:	$4 000.00
Gross Profit:	$0 (0.00 %)
EPS:	$-1.050

Q3	2023
Revenue:	$0
Gross Profit:	$-1 000.00 (0.00 %)
EPS:	$-0.750

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.150

Financial Reports:

No articles found.

Neurobo Pharmaceuticals

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.